跳到正文
原文
Moderna· @moderna_tx · X·· 26 天前精选AI 评分82
AI 导读

Moderna公布III期INTerpath-001研究的详细阳性结果,该研究评估intismeran autogene(mRNA-4157或V940)联合默沙东抗PD-1疗法KEYTRUDA(帕博利珠单抗),用于完全切除后的高危黑色素瘤(IIB-IV期)患者。

推荐理由

Moderna公布个体化新抗原疗法联合KEYTRUDA在高危黑色素瘤术后辅助治疗中的III期详细阳性结果,读者可据此了解该联合方案的关键临床进展。

正文

Today we announced detailed positive results from the Phase 3 INTerpath-001 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab), @Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage IIB-IV) following complete resection.

These late-breaking results will be presented during a Presidential Symposium at the 2026 European Society for Medical Oncology (@myESMO) Congress.

Read more: https://feeds.issuerdirect.com/news-release.html?newsid=8277620888059962&symbol=MRNA

来源:Moderna · x.com